LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma.

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.

HMBD-001 is under clinical development by Hummingbird Bioscience and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...